Company earnings

MAZE Earnings Date & History

Maze Therapeutics Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.

Last updated Aug 19, 2026 at 4:07 PM ET

Maze Therapeutics Inc

Pharmaceuticals

Next earnings date
Monday, November 2, 2026
Reporting session
Time TBD
EPS estimate
$-0.80
Revenue estimate
$0

MAZE earnings history

Report dateQuarterEPS est.EPS actualSurpriseRevenue
Tuesday, May 12, 2026Q1 2026$-0.56$-0.45+19.1%$20.0M
Wednesday, March 25, 2026Q4 2025$-0.73$-0.65+10.7%$0
Thursday, November 6, 2025Q3 2025$-0.72$-0.66+8.7%$0
Tuesday, August 12, 2025Q2 2025$-0.87$-0.77+11.8%$0

What the market is watching in MAZE's next report

  • The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
  • Ticker Read combines trend, relative strength and catalysts in one research view.
  • Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Free by email

Get the week's earnings by email

One free email each week: the reports that matter, when they land, and what the market is watching.

No account required. Unsubscribe any time. Research and education only — not investment advice.

Frequently asked questions

When is the next MAZE earnings date?
Maze Therapeutics Inc is scheduled to report on Monday, November 2, 2026 (Time TBD). Dates can change until the company confirms them.
Does MAZE report before or after the market?
The next report is scheduled time tbd.
What EPS is expected for MAZE?
Consensus EPS for the upcoming quarter is $-0.80, on revenue of $0.

Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.

MAZE earnings discussion

Anyone can read. Any free Hyper Stocks account can join in.

Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.

Loading discussion…

Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.